Microneedles made of monocrystalline silicon are at the core of Ascilion's dISF sampling solution. Hollow microneedles combined with a capillary system enable robust sampling and collection of dISF. With a needle length of less than 0.5 mm, the sampling process is truly minimally invasive.
The PELSA system is used worldwide to reliably and painlessly extract dISF for high-quality biomarker analysis.
Unlock the full potential of your sensing technology with controlled access to dISF.
Ascilion supports biosensor development and validation using actual biological fluid, enabling more accurate testing and accelerating the path toward clinical readiness.
Our sampling assemblies extract and deliver dISF directly to the biosensor in your wearable. This reduces development complexity, simplifies regulatory strategy and shortens time to market.
At Ascilion we are focused on solving one of healthcare’s biggest challenges: how to access all the body’s biomarkers painlessly and in real time. Our unique approach is built on years of collaboration with researchers and industry partners, always with the patient and the customer at the center of everything we do.
Simon Grant, CEO
